Lead the market access strategy and execution of Abeona's lead candidate, prademagene zamikeracel (pz-cel), an autologous, engineered cell therapy for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB).

• Report directly to the Chief Executive Officer• Assumed all commercialization responsibilities from previous Chief Commercial Officer.• Lead the commercial access strategy for lead autologous cell therapy candidate for the treatment of ALS.• Develop, deliver, and execute complete RFP process for patient services providers to support launch. • Negotiate and manage Commercialization partner on key deliverables including market access landscape, value and access strategy, reimbursement, pricing and contracting, government reporting and field support.• Uncover and present potential partnership opportunities through various business development deals.• Selected as Industry representative panelist at the PCMA annual meeting, September 2022, to discuss and debate the topic of “how manufacturers and payers can collaborate to support patient outcomes.”* downsized due to negative FDA Advisory Committee outcome leading to organizational restructuring and BLA being pulled from consideration.

* Highly successful launch of the highest priced therapy ever developed at the time, Zolgensma, a Gene Replacement Therapy (GRT) for the treatment of Spinal Muscular Atrophy in infants. * Department Head for Market Access and Patient Support Services teams (26) inclusive of National Account Directors, Field Reimbursement Managers, Patient Access Managers (Nurse Navigator), and Contracting Director.

Channel, Distribution, and Market Access Launch strategy development for a novel gene therapy treatment for a rare genetic neurological condition, Spinal Muscular Atrophy (SMA).

ELAN ACQUISITION of DURA PHARMACEUTICALS - February 2000Promoted to Sales Management - May 2000